Hemab Therapeutics Holdings, Inc.
COAGNasdaq
$49.29
↑ +10.7%Jul 17 close · end-of-day
Price
1Y↑ +45.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Our principal executive offices are located in Cambridge, MA.
- CEO
- Benny Sørensen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 72
- Headquarters
- Massachusetts
- Website
- www.hemab.com
Earnings
COAG Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$23.98↑ +48.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$16.6M | -$23.6M |
| Net income | -$15.3M | -$22.7M |
| Diluted EPS | -$16.18 | -$23.98 |
| Operating cash flow | -$13.0M | -$21.6M |
| Free cash flow | -$13.0M | -$21.7M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | RA CAPITAL MANAGEMENT, LLC | Buy | 61,523 | $24.98 | $1.5M | filing |
| 2026-06-15 | RA CAPITAL MANAGEMENT, LLC | Buy | 6,146 | $24.89 | $152,973.94 | filing |
| 2026-05-20 | RA CAPITAL MANAGEMENT, LLC | Buy | 996 | $24.94 | $24,840.24 | filing |
| 2026-05-19 | RA CAPITAL MANAGEMENT, LLC | Buy | 3,802 | $24.97 | $94,935.94 | filing |
| 2026-05-12 | RA CAPITAL MANAGEMENT, LLC | Buy | 6,387 | $24.90 | $159,036.30 | filing |
| 2026-05-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 25,720 | $25.00 | $643,000.00 | filing |
| 2026-05-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 14,149 | $24.47 | $346,226.03 | filing |
| 2026-05-08 | RA CAPITAL MANAGEMENT, LLC | Buy | 1,483 | $24.98 | $37,045.34 | filing |
| 2026-05-07 | RA CAPITAL MANAGEMENT, LLC | Buy | 7,921 | $24.34 | $192,797.14 | filing |
| 2026-05-07 | RA CAPITAL MANAGEMENT, LLC | Buy | 1,985 | $24.95 | $49,525.75 | filing |
| 2026-05-06 | RA CAPITAL MANAGEMENT, LLC | Buy | 53,407 | $24.83 | $1.3M | filing |
| 2026-05-06 | RA CAPITAL MANAGEMENT, LLC | Buy | 14,611 | $23.77 | $347,303.47 | filing |
| 2026-05-05 | RA CAPITAL MANAGEMENT, LLC | Buy | 87,143 | $24.59 | $2.1M | filing |
| 2026-05-05 | RA CAPITAL MANAGEMENT, LLC | Buy | 10,268 | $25.00 | $256,700.00 | filing |
| 2026-05-04 | RA CAPITAL MANAGEMENT, LLC | Buy | 2,541,250 | $18.00 | $45.7M | filing |
| 2026-05-04 | RA CAPITAL MANAGEMENT, LLC | Buy | 133,750 | $18.00 | $2.4M | filing |
| 2026-05-04 | MARAGANORE JOHN | C | 17,974 | — | — | filing |
| 2026-05-04 | MARAGANORE JOHN | C | 17,974 | — | — | filing |
| 2026-05-04 | RA CAPITAL MANAGEMENT, LLC | C | 3,607,846 | — | — | filing |
| 2026-05-04 | RA CAPITAL MANAGEMENT, LLC | C | 1,009,052 | — | — | filing |
| 2026-05-04 | RA CAPITAL MANAGEMENT, LLC | C | 221,188 | — | — | filing |
| 2026-05-04 | Novo A/S | C | 4,180,550 | — | — | filing |
Latest 22 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.